# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target ...
Cantor Fitzgerald analyst Louise Chen reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Overweight.
Zevra Therapeutics reported its second-quarter financial results Tuesday. Here's a look at the details.
Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of ...
The offering is expected to close on August 12, 2024, subject to customary closing conditions.